# Johnson & Johnson Type: Company Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/johnson-johnson Canonical HTML page: https://getbiobrief.com/entity/johnson-johnson ## Timeline - **2026-03-18**: Quarterly Earnings — Expected announcement of financial results and pipeline updates for PTGX and OEZVY. - **2026-03-12**: BofA Price Target Hike — Bank of America increases price target, highlighting R&D productivity and MedTech growth. - **2026-03-07**: Fast-Track Approval — USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program. - **2026-03-05**: 12-Month High — JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo. - **2026-02**: TGA Approval — Australian regulatory body approves the Virtual Nodule Clinic for clinical use. - **2025-11-01**: Pipeline Update — Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference. - **2025-Q4**: JNJ-2113 Phase 3 Progress — Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials. - **2025-06-15**: Manufacturing Expansion — Obelisc facility in Belgium reaches full operational status for clinical and commercial supply. - **2025-03-10**: FY 2025 Earnings — Legend Biotech reports full-year results and commercial highlights. - **2024-01-31**: Takeda Partnership — Protagonist signs a global licensing agreement for rusfertide with $300M upfront. - **2022-09**: Series A Funding — Company raises $14M to scale its AI clinical platform globally. - **2021-03**: FDA Clearance — Optellum receives first-of-its-kind FDA clearance for AI lung cancer decision support. ## Recent coverage (8 stories) ### J&J Clears $5.5B Talc Overhang: Refocusing on $85B Pharma Pipeline 2026-07-28 14:39:57 · Sentiment: Bearish · Impact: 7/10 · Sources: 3 The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue. Full story: https://getbiobrief.com/story/jnj-talc-settlement-pharma-outlook ### 500+ Tylenol suits revived: $10B risk for Kenvue and OTC pharma 2026-07-25 19:56:51 · Sentiment: Bearish · Impact: 7/10 · Sources: 2 The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy. Full story: https://getbiobrief.com/story/tylenol-autism-lawsuits-revived-bio ### Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones 2026-03-17 07:33:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity. Full story: https://getbiobrief.com/story/protagonist-therapeutics-verbund-earnings-preview-2026 ### BofA Bullish on Johnson & Johnson as Pipeline Momentum Accelerates 2026-03-12 08:11:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets. Full story: https://getbiobrief.com/story/bofa-jnj-price-target-pipeline-growth ### Legend Biotech Reports Robust 2025 Growth Driven by Carvykti Scaling 2026-03-10 13:50:46 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market. Full story: https://getbiobrief.com/story/legend-biotech-q4-2025-results-carvykti-growth ### Optellum Secures TGA Approval for AI Lung Cancer Solution in Australia 2026-02-27 02:36:24 · Sentiment: Bullish · Impact: 7/10 · Sources: 3 Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively. Full story: https://getbiobrief.com/story/optellum-tga-approval-lung-nodule-ai-australia ### Protagonist Therapeutics Surges 120% as Major Fund Trims $170M Stake 2026-02-25 21:44:08 · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer. Full story: https://getbiobrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit ### Genmab Navigates Revenue Miss as 2026 Guidance Signals Strategic Pivot 2026-02-19 08:26:16 · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse. Full story: https://getbiobrief.com/story/genmab-q4-2025-earnings-analysis-revenue-miss-2026-guidance --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.